MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, has been informed by the American Medical Association (AMA) that in its summary of panel actions September 2019 meeting, the CPT® Editorial Panel accepted the addition of new Category III codes 0X30T, 0X31T to report “wound bacterial localization and treatment” effective date July 1, 2020 to enable a reimbursement pathway for point-of-care fluorescence wound imaging. At that time a novel code excluding the “X” will be reported by the AMA when the final datafiles are distributed by the AMA. Point-of-care fluorescence wound imaging is achieved using MolecuLight’s handheld fluorescence imaging device, the i:X®.
Category III CPT Codes are temporary codes for emerging technologies and procedures that allow for specific data collection associated with the work and costs of the procedures. Reimbursement for procedures reported with a Category III code is at the payer’s discretion. As these procedures become more commonly adopted and established, MolecuLight will continue to work with the AMA to move these codes from Category III to Category I CPT status.
To read more, please click the PDF above or visit their website.